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2. ABSTRACT 
Therapeutic balloon angioplasty causes an abrupt injury to a vessel wall and alters elements of 
vascular wall repair, especially inflammatory processes. The net benefit of stent implantation is an 
attribute to the larger initial lumen gain and the prevention of negative remodelling. In addition to 
in-stent restenosis, stent implantation may be complicated by (sub)acute thrombosis, or by possible 
rare complications, such as infection, vessel perforation, immunologic reaction, or corrosion. As a 
result, various antithrombotic and antiproliferative stent coatings and alternative stent materials 
have been developed. The aim of this study was firstly to evaluate the utility of polylactide (PLA) 
as stent core material using simple stent prototypes. Secondly, thrombogenicity of PLA in 
comparison with stainless steel was assessed. An additional goal of this study was to explore 
whether it was feasible to improve the haemocompatibility of PLA by coating it with unfractionated 
releasable heparin. 
 
Twenty adult New Zealand White (NZW) rabbits were used as test animals for surgical aortic PLA 
stent implantation. Tissue reactions were evaluated at various time points from one to 34 months 
after stent implantation by histologic assessments and by scanning electron microscopy (SEM). In 
general, tissue reactions were mild in response to stent implantation, and the PLA stents degraded 
within 24 months. The conclusion was that PLA is useful as a stent core material for future 
biodegradable stent designs. 
 
Next, the possibility of measuring intraluminal dimensions by magnetic resonance angiography 
(MRA) after PLA stent implantation was investigated. Twelve spiral PLA stents and six stainless 
steel (SS) stents were implanted into NZW rabbit aortas, with additional six rabbits serving as a 
non-operated control group for imaging studies. Aortic measurements were established with a 1.5 T 
magnetic resonance (MR) scanner by the use of computerised measurements. Six PLA-stented 
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animals were followed-up to one year after stent implantation, and histology and SEM were 
performed at the end of the study. PLA stents were translucent in conventional MR scanning, while 
SS caused a signal loss. In conclusion, PLA stents allow luminal visualisation by MRA straight 
after stent implantation and during the early phase of biodegradation. However, a marking system 
should be created for small-vessel PLA stents. 
  
Signs of blood compatibility of stainless steel and unheparinised and heparinised polylactide stent 
struts were assessed by using a steady state model with human blood. The aim was firstly to 
challenge the natural anticoagulative factors, and secondly, to assess the procoagulant capacity of 
platelets in the presence of a stent strut. Platelet deposition and morphology were studied, as well as 
various markers for coagulation activation. At physiological platelet densities, more platelets 
adhered to SS than to PLA per stent strut area. Thrombin time (TT) values were prolonged in all 
assessments for heparin-coated PLA struts. The interpretation was that PLA is at least as 
haemocompatible as stainless steel, and when heparinised, PLA may be of further benefit. 
 
Finally, blood compatibility of different PLA stents in comparison with stainless steel stents was 
examined applying a whole blood perfusion model. The stents were first perfused without 
precoating, and then, to mimic the pathophysiology of balloon injury related to stenting, by 
precoating the stent containing segment of the perfusion tubing with fibrillar type I collagen. 
Quantitively, SS stents collected the least platelets under all study conditions. Among all 
biodegradable stents, the braided stent coated with polycaprolactone-polylactide-heparin 
accumulated the fewest platelets. In conclusion, under flowing conditions, PLA stents were not as 
haemocompatible as SS stents, but heparin coating increased the blood compatibility of PLA stents. 
Therefore, the design of biodegradable stents must be further developed before clinical studies are 
planned. 
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3. INTRODUCTION 
 
Percutaneous transluminal angioplasty (PTA), with or without stenting, has become a treatment of 
choice in selected patients with coronary and peripheral atherosclerotic lesions (Fischman et 
al.1994, Serruys et al. 1994, Hsieh et al. 2001, TASC Investigators 2000). Despite the indisputable 
advantages of PTA, this kind of treatment may be complicated by (sub)acute thrombotic occlusion 
or restenosis (Schömig et al.1996, Fischman et al.1994), or by possible stent-related complications, 
such as infection (Therasse et al. 1994, Hearn et al.1997, Doslouglu et al. 2001), vessel perforation 
(Smith et al. 2001, Korpas et al. 2002), immunologic or foreign-body reactions (Yutani et al. 1999), 
or corrosion (Ryhänen et al. 1997). Since the introduction of stents to clinical practice over 20 years 
ago, much effort has been expended to deal with thrombogenicity and in-stent restenosis. The 
development of periprocedual medications, and in particular introduction of antiplatelet and 
anticoagulative treatment in the modern era, have greatly diminished rates of early thrombotic 
occlusions (Orford et al. 2002). The problem of in-stent restenosis appears to be remarkably 
delayed, or perhaps even resolved, by the use of novel antiproliferative stent coatings such as 
sirolimus (rapamycin) and paclitaxel (Morice et al. 2002, Park et al. 2003, Schampaert et al. 2004).  
 
Balloon angioplasty causes abrupt injury to the vessel. Adhesion, activation, aggregation, and 
deposition of platelets as well as inflammatory cells occur at the injured site. After the thrombotic 
period of healing, the repair process takes a much longer time, at least several weeks, firstly in the 
recruitment phase and secondly in the proliferative phase (Hofma et al. 2001). Despite the positive 
effects of stents, especially prevention of elastic recoil and abrupt vessel closure, these conventional 
permanent devices can cause a longer-lasting injury to the vessel wall and more pronounced long-
term endothelial dysfunction than simple PTA (van Beusekom et al. 1998). Implanting a stent is 
introducing a foreign body into tissue and into contact with blood, thus biocompatibility and 
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haemocompatibility are two major issues that must be dealt with. Consequently, it seems logical 
that prevention of these possible undesirable effects by improving stent properties would be more 
effective than treatment of the complications.  
 
Therefore, both different stent coatings and alternative stent materials have been developed. 
Heparin- and hirudin-coatings have been directed against the clotting cascade (Seifert et al. 1995, 
Alt et al. 2000). Various antiproliferative agents, such as angiopeptin analogues, methotrexate, 
dexamethasone, paclitaxel, and sirolimus among others (Cox et al. 1992, De Scheerder et al.1996a, 
Lincoff et al.1997, Betrtrand et al. 1998, Morice et al. 2002, Park et al 2003), as well as irradiation 
(Tierstein and Kuntz 2001) have been used to fight against the proliferative process leading to 
intimal hyperplasia and restenosis/in-stent restenosis. On the other hand, corrosion of metals may 
stimulate fibroblast growth, platelet deposition, and protein adhesion, which consequently may 
cause stenosis in the stented area (Ryhänen et al.1997, Shih 2001), but this has not yet been proven 
with stents. Furthermore, Hoffmann et al. (1996) have suggested that some early positive effects of 
stent implantation may be diminished by hindrance of the late, favourable luminal remodelling. As 
a result, new stent materials, either biostable or biodegradable, have been sought. 
 
Among biodegradable materials, polylactide (PLA) is one of the most employed materials in 
medicine, showing excellent biocompatibility in various tissues, but not without controversy in 
vascular applications, mainly due to the previously described inflammatory reactions (van der 
Giessen et al. 1996, Lincoff et al.1997, Su et al. 2003). Currently available stents are made of 
various metals and are mostly permanent. Theoretically, bioabsorbable devices could offer some 
benefits over permanent ones. They would not remain as foreign bodies in the target tissue, after 
serving as intravascular dilators through the most vulnerable phases of healing after PTA, allowing 
positive late luminal remodelling. Therefore, any recurrent procedure, in the form of repeated PTA 
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or revascularisation, would not be interfered with. Secondly, the absorption time in tissues could be 
tailored, as this depends on the choice of basic molecule(s), degree of polymerisation, internal 
arrangement of the material components, stent configuration, method of sterilisation, site of 
implantation (Törmälä et al. 1998), and biomechanical stresses and forces (Miller and Williams 
1984). Thirdly, in addition to serving as small vessel dilators and as carriers for drugs and genes, 
bioabsorbable devices could be used in the treatment of venous or congenital vascular strictures or 
peripheral arteriosclerotic lesions, extending the applications of stents (Bertrand et al. 1998). 
 
This study was designed firstly to examine tissue compatibility of poly-L/D-lactide stents in small 
vessels in a normal rabbit aorta model, and secondly, to experimentally evaluate signs of early 
biodegradation and determine the possibility for measurement of luminal dimensions after stent 
implantation by magnetic resonance angiography (MRA). Finally, thrombogenicity of polylactide in 
comparison with stainless steel was investigated by two different in vitro models with human blood. 
The effect of coating the core material, PLA, with heparinised as well as non-heparinised resorbable 
materials, was also assessed with these in vitro human blood models. 
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4. REVIEW OF THE LITERATURE  
 
4.1. Treatment of atherosclerosis  
Therapeutic regimens in atherosclerosis have undergone a fundamental change during the past few 
decades, not only due to better understanding of the cellular and molecular mechanisms involved in 
the development of the disease,  but also as a result of the development of both medical treatment 
and  interventional techniques. Furthermore, the “conservative treatment” is no more conservative, 
and instead consists of an active policy to decelerate progression of the disease and to prevent 
complications. This includes controlling risk factors such as high lipid levels, hypertension, 
smoking, lack of exercise, and obesity. Furthermore, preventive medical treatment of risk groups, 
especially of diabetic patients, includes therapy with β-blockers, statins, angiotensin converting 
enzyme (ACE) inhibitors, and antiplatelet/anticoagulative agents (Pearson et al. 2002, Caprie 
steering committee 1996, Bhatt and Topol 2000, Bhatt et al. 2002, Steinhubl et al. 2002, Serruys et 
al. 2002, Gomma et al. 2002). Ongoing and future trials will evaluate the role of antiplatelet 
regimens in the prevention and management of coronary, cerebral, and peripheral vascular diseases. 
 
When it comes to interventional techniques, along with the introduction of advanced percutaneous 
techniques a revolution has taken place over the past 20 years. Conventional bypass surgery, in the 
treatment of both coronary and peripheral artery lesions, has quite often become “the last chance” 
for revascularisation. Instead, PTA, combined often with stenting and always with appropriate 
medical therapy, is the predominant therapeutic option in the treatment of chronic ischemia due to 
coronary or supragenicular atherosclerotic lesions, whenever lesion morphology and the clinical 
situation are favourable for this kind of procedure. Acute ischemic attacks can often be managed by 
either thrombolysis – frequently combined with concomitant percutaneous intervention – or bypass 
surgery, depending on the clinical situation and available medical and technical resources. 
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Endoluminal grafting is widely applied in clinical practice, although its position as a treatment 
option is under evaluation, as long-term results are being published (Harris et al. 2000, Aho et al. 
2002, Bray et al. 2003). The possible benefit from minimally invasive surgical approaches, in both 
coronary and peripheral vascular surgery, is also under investigation (Acikel et al. 2001, Turnipseed 
et al. 2003, Ohtsuka et al. 2003, Bonatti et al. 2003). Combining percutaneous and surgical 
approaches, i.e., hybrid techniques have also become clinical practice in selected cases (Melliere et 
al. 1999, Sinci et al. 2000, Lawrence-Brown et al. 2000, Schneider et al. 2001, Stahl et al. 2003).  
 
 4.2. Evolution of percutaneous transluminal angioplasty (PTA) and stenting 
Over 50 years ago, the Swedish doctor Sven-Ivar Seldinger introduced the idea of a percutaneous 
entry technique to gain access to any part of the cardiovascular system (Seldinger 1953). Roughly a 
decade later, Dotter and Judkins (1964) described the principle of transluminal catheter dilation, and 
the idea of endovascular tubular grafting was introduced in 1969 (Dotter 1969). The invention of a 
balloon dilation catheter created a real revolution in the treatment of atherosclerotic lesions, and the 
first clinical results of non-operative dilation of coronary arteries were reported in 1978 (Grüntzig 
1978). Along with the development of new intravascular supporting devices, the term “stent” was 
introduced, based on the surname of the British dentist Charles Stent, who had first applied a related 
device in 1856 (Ring 2001). Currently, PTA, often combined with stenting, has become the first 
choice of interventional therapy in most coronary, renal, and suprainguinal peripheral artery lesions. 
In coronary arteries, stents markedly reduce restenosis rate (Kiemeneij et al. 2001, Schiele et al. 
2003, Brophy et al. 2003), and they can be used to prevent abrupt vessel closure and to treat vessel 
dissections, thus reducing the need for acute operative interventions.  
 
The treatment of infrainguinal atherosclerotic lesions by PTA remains challenging, as the long-term 
patency rates have been somewhat disappointing, despite good primary success. Often, such as in 
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the case of critical limb ischemia, selection between percutaneous, hybrid, or surgical approaches 
depends greatly on each individual’s concomitant diseases and operability, in addition to the 
morphologic angiographic situation (TASC Investigators 2000). Presently, PTA is applied widely in 
the treatment of venous disorders, although long-term reports are scarce (Lamont et al. 2002, Raju 
et al. 2002, De Gregorio et al. 2003, Kalra et al. 2003). New antiplatelet drugs and the development 
of stent design and coatings, however, may both improve long-term results of stenting and extend 
applications of stents in the near future. 
 
4.3. Vascular response to PTA and stenting 
Nowadays, the differences between vascular biological responses to balloon- and stent-induced 
injuries are recognised (Schober et al. 2002). Welt and Rogers (2002) have presented an integrated 
view of the pathophysiologic events underlying in-stent restenosis (Figure 1). Deendothelialisation 
after stent implantation is followed by immediate deposition of a layer of platelets and fibrin at the 
injured site. Adhesion molecules (e.g. P-selectin and glycoprotein Ibα) secreted by activated 
platelets attach to circulating leukocytes via platelet receptors, and a process of rolling along the 
injury site begins (Kuijper et al. 1998). With the aid of cytokines, leukocytes bind to the leukocyte 
integrin class of adhesion molecules through direct attachment to platelet receptors, cross-linking 
fibrinogen to the glycoprotein IIb/IIIa receptor. Smooth muscle cells and resident leukocytes release 
cytokines, which stimulate the migration of leukocytes across the platelet-fibrin layer into the 
tissue. Platelets, leukocytes, and smooth muscle cells release growth factors, which influence the 
migration of smooth muscle cells from the media to the neointima and their proliferation. In this 
phase, the formed neointima has smooth muscle cells, extracellular matrix, and macrophages, 
recruited over a period of several weeks. In the final phase of healing, cellular elements are replaced 
by a production of extracellular matrix, and at least partial reendothelialisation takes place (Welt 
and Rogers 2002), usually within three weeks (Lindner et al.1993). Monocyte-derived  
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Figure 1. Cross-sectional, simplified presentation of pathophysiologic events in the intima and media 
after percutaneous angioplasty and stenting resulting in in-stent restenosis. Modified from Welt and 
Rogers, 2002. Stent implantation leads to endothelial denudation and deposition of platelets and 
fibrinogen (B). Leukocyte rolling, recruitment, and infiltration, and smooth muscle cell (SMC) 
migration and proliferation occur during the first days after vascular injury (C and D). Neointimal 
thickening is detectable within a few weeks following the injury, and SMC proliferation and 
monocyte recruitment continue (E). During the following weeks and months, the cellular content of 
the neointima diminishes and is replaced through production of extracellular matrix (ECM). Finally, 
a restenotic lesion develops. PDGF = Platelet-derived growth factor, TGFβ = Transforming growth 
factor-beta, VEGF = Vascular endothelial growth factor 
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macrophages seem to be associated with lesion progression, due to persistent secretion of cytokines 
and growth factors (Ip et al.1990). Some recent data suggest that somatic stem cells may also play a 
pivotal role in the pathological remodelling of the vessel wall after angioplasty (Sata et al. 2002, 
Kang et al. 2004). 
 
 Clinically, stenting appears to incur greater neointimal growth than PTA, but the net benefit of 
stent implantation is attributed to the larger initial lumen gain and the prevention of negative 
remodelling (Fischman et al. 1994, Serruys et al. 1994, Hoffmann et al. 1996). Furthermore, there is 
some evidence that an increased inflammatory response may explain the larger neointimal growth 
in stented arteries than in balloon-dilated arteries (Inue et al. 2000).  In clinical stent thrombosis, the 
role of platelets is also known to be essential, coinciding with such factors as the extent of vascular 
injury, errors in stent design and engineering, incomplete stent expansion, ineffectiveness of 
antithrombotic therapy, and the thrombogenic nature of metallic surfaces. In addition to activated 
endothelial cells, platelets contribute to accumulation of leukocytes and to changes in their behavior 
in both physiological and pathological conditions, emphasising the intimate relationship between 
thrombosis and inflammation (Weyrich et al. 2002).  
 
4.4. Stent materials 
Material characteristics, bulk and surface properties, stent configuration, and chemistry are pivotal 
factors to be taken into account in the creation of an ideal intravascular stent. An optimal stent 
should be easily delivered with appropriate expandability, strength, and elasticity. Furthermore, it 
should be haemocompatible, allowing complete endothelialisation and positive vessel remodelling, 
and it should induce neither neointimal overgrowth nor restenosis. To date, all clinically applied 
stents are made of various metals, although there have been numerous attempts to design stents 
made of other materials over the past decades. All stent materials can be roughly divided into two 
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main categories, biostable or biodegradable/absorbable, but as stent coatings have recently been 
applied both experimentally and clinically, a third category of partly biostable, partly degradable 
stents has emerged, into which category many coated stents fall. 
 
 4.4.1. Biostable materials 
The first stents introduced were coilsprings made of stainless steel (SS) wire (Dotter 1969). The 
most applied stents are nowadays made of stainless steel, nitinol (nickel-titanium) or tantalum. SS is 
most often 316L alloy, L indicating low carbon content, with the predominant contents being iron, 
chromium, and nickel. The chromium contributes strength and hardness, and good corrosion 
protection (Park 1995). Self-expanding nitinol alloys have shown good biocompatibility as stents, 
although there is a theoretical concern of possible nickel leakage resulting in immunogenic 
reactions. Devices made of tantalum have a few theoretical advantages over SS: radiopacity, 
biocompatibility, mechanical properties, and lack of ferromagnetism. In vivo tantalum stent wires 
undergo oxidation, which results in extremely stable surface properties (Taylor 1996).  Polishing 
appears to reduce thrombogenecity of SS and nitinol stents (De Scheerder et al. 1998, Sheth et al. 
1996a, Fontaine 1996). Clinically, however, it is uncertain if there is any advantage in vivo based on 
the choice of the basic metal itself. Stent design, surface and mechanical properties, and stent-
induced vessel injury seem to be more important issues (Fontaine et al.1994, Hehrlein et al. 1995, 
Barth et al. 1996, Sheth et al. 1996a, De Scheerder at al. 1998, Taylor et al. 2001, Farb et al. 2002). 
 
 4.4.2. Biodegradable materials 
Polylactide (PLA) 
Since their introduction as bioabsorbable surgical materials in the 1960’s and 1970’s, polymers such 
as polyglycolic acid (PGA) and PLA have been widely used as suture material (Dexon®, Vicryl®), 
and as fixation devices (screws, pins, plates) in orthopaedics, traumatology, and plastic surgery 
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(Böstman et al. 1990, Törmälä and Pohjonen 1995, Suuronen et al.1999, Weisberger and Eppley 
1997). As tubular duct devices, stents made of polymers have been introduced in urology (Petas et 
al. 1997), gastroenterology (Parviainen et al. 2000) and, in the future, perhaps as an alternative to 
treat airway stenosis as well (Korpela et al. 1999). Whether biodegradable materials are suitable in 
routine intravascular applications is still, however, under evaluation (Michalis 2002, Tamai 2000).  
 
Polylactic acid is derived from the cyclic diester of lactic acid by ring-opening polymerisation, 
producing a poly-α-hydroxy derivate of the original acid (Gilding and Reed 1979). The clinically 
important polymers of PLA are macromolecules with molecular weights from tens of thousands of 
daltons to more than one millon daltons. The asymmetric polylactic acid has two st ereoisomeric 
forms, L- and D-isomers (Cutright et al. 1974, Connor et al. 1983) (Figure 2). The L-isomer exists 
in normal human carbohydrate metabolism, and the D-isomer is detectable in urine and in acidic 
milk. If a polymer is formed by one type of monomer, it is called homopolymer (e.g. poly-L-lactic 
acid, PLLA). A copolymer consists of two types of monomers (e.g. poly-D,L-lactic acid, PDLLA). 
The strength of the polymer depends on the basic molecule, the length of the chain, and the 
microstructure (Törmälä 1992). In general, randomly oriented and loosely -packed polymeric chains 
are amorphous and weak. On the contrary, parallel, tightly-packed polymers are more crystalline 
and stronger. Such polymers are self-reinforced through the die-drawing method, in which long 
molecules become parallel and form microfibrils increasing strength, modulus, and toughness 
(Törmälä 1992). As part of the microstructure is oriented into reinforcement elements, the material 
receives metal-like properties. 
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Figure 2.  Polylactide is polymerised from a lactic acid dimer. Lactic acid occurs in two 
stereoisomeric forms, L(+) and D(-). 
 
 
Biodegradation of a polymer implanted in a biological environment can be defined as its 
disintegration by hydrolysis, enzymes, or bacteria (Chu 1981). The speed of biodegradation 
depends on the choice of the basic molecule(s), molecular weight, configuration and thickness of 
the material, site of implantation, biomechanical stress to which the implant is exposed, and 
 21
impurities (presence of low molecular weight compounds, monomers, and D-isomers) (Törmälä 
1992, Törmälä et al. 1998, Miller and Williams 1984). Poly-L-lactide is de-esterified into lactic acid 
by hydrolysis and converted to puruvate and then to acetyl-CoA in the citric acid cycle in the 
mitochondria. The end products carbon dioxide and water are excreted via respiration and urine 
(Kulkarni et al. 1966, Brandy et al. 1973, Williams 1982, Hollinger and Battistone 1986). The 
metabolism of poly-D-lactide is presumably enabled by a mitochondrial enzyme, which catalyses 
the oxidation of D-lactate to pyruvate (Connor et al.1983). The degradation of PLA can be 
accelerated by cellular enzymes (Williams 1982, Vasenius et al. 1990) and free radicals (Williams 
1992, Ali et al. 1993). 
 
The biocompatibility of PLA is relatively good in biological environments other than 
intravascular, as evidenced by limited, mild inflammatory reactions and foreign body reaction 
around the implanted material (Kulkarni et al. 1966, Cutright et al. 1971, Cutright and Hunsuck 
1971, Rokkanen et al. 1985, Majola et al. 1991, Törmälä 1992). Rarely, an aseptic soft tissue 
response after bone plate fixation is possible, presumably due to remnants of slowly degrading 
PLA (Bergsma et al. 1995). Stents made of PLA, as well as PGA, have previously been employed 
with promising results, as a treatment of choice after prostatectomy to avoid voiding problems 
(Talja et al. 1995, Petas et al. 1997). In addition, experimental data have demonstrated excellent 
tissue compatibility in the treatment of experimental tracheal stenosis (Korpela et al. 1998). 
 
The experimental data of PLA’s biocompatibility in intravascular applications has been partly 
controversial so far: the inflammatory responses have varied from very mild to severe. The first in 
vivo studies with a bioabsorbable stent were performed by researchers at Duke University in the 
late 1980’s (Zidar 1994). This stent was made of poly-L-lactide, with at least comparable or even 
better radial strength than a comparable stainless steel stent. The stents, with a maximal lumen of 4 
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mm, were dilated in femoral arteries of 11 mongrel dogs, and followed up to two years after 
implantation. Of the 11 stents, nine remained patent for follow-up. Histologic sampling revealed 
minimal thrombus formation, moderate neointimal growth, and limited inflammatory reaction. The 
stent had disintegrated by 9 months. Some data indicates that an inflammatory reaction depends 
greatly on the molecular weight of the implanted polymer. In metallic stents coated with low 
molecular weight (80 kDa) poly-L-lactide, Lincoff et al. (1997) noted more severe vascular 
response with acute and chronic inflammation than in those coated with high molecular weight 
(321 kDa) poly-L-lactide. The only human study with biodegradable poly-L-lactide stents was 
published recently (Tamai et al. 2000), and had a follow-up period of six months after the stent 
implantation in coronary arteries. The long-term data, including the presumable period of stent 
disintegration, have not been reported.  
 
Polycaprolactone (PCL) 
Poly-epsilon-caprolactone (PCL) is, like PLA, a biodegradable aliphatic polyester which 
undergoes a two-stage degradation process: firstly, hydrolytic cleavage of ester groups begins non-
enzymatically, and then in the second phase the polymer becomes more highly crystalline, and its 
molecular weight is reduced. Experimental studies suggest that the intracellular degradation of 
PCL is the main pathway of degradation in vivo (Woodward 1985). When equal quantities of L-
lactide and epsilon-caprolactone are synthesised to form a copolymer, crystallised PLA blocks 
seem to be much more resistant to biodegradation than PCL in vitro (Li et al. 1996). PCL has been 
tested as a carrier substance in various kinds of tissue engineering experiments, for drug or gene 
transfer, often as copolymeric material (Kweon et al. 2003, Woo et al. 2000, Ye et al. 1998). 
Clinically, a triblock-copolymer of PCL and polydimethylsiloxane has been tested in 
cardiopulmonary bypass surgery as an antithrombogenic circuit coating (Rubens et al. 1999). 
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stents in human arteries has also been reported (Marc Bosiers, oral presentation, Charing Cross 
International Symposium, London, 3th-6th April, 2004).  These stents were percutaneously 
delivered after angioplasty into human superficial femoral arteries in a small series of patients with 
promising short-term results.   
 
4.4.3. Coated stents 
Stent coatings have been developed for two main purposes: for ameliorating haemocompatibility 
and for diminishing neointimal overgrowth. Several techniques (dipping, spraying, plating, 
sputtering, and surface-induced mineralisation) as well as coatings (inorganic, ceramic, and 
polymeric materials, immobilised or releasable drugs with degradable or stable matrices) have been 
employed. Some of these materials have been tested for effective coating, and others have been 
used for efficient drug delivery (Bertrand et al.1998). In addition, endothelial cell seeding, as well 
as surface-incorporated gene vectors have been tried on stents (Ye et al. 1998, Yamawaki et al. 
1998, Scott et al. 1995, Kutryk et al. 1998, Flugelman et al. 1992, Dichek et al. 1989). Despite 
encouraging experimental data, many of these coatings have failed clinically, and even adverse 
effects have occurred (Kastrati et al. 2000a).  
 
Antithrombotic stent coatings 
Among thromboresistant stent coatings, heparins are the most extensively investigated drugs. They 
can be absorbed or immobilised on a stent surface in three ways: ionically, by mixing with a 
polymer, or by covalent binding (Table 1). The principal anticoagulant mechanism of 
unfractionated heparin is dependent on its interaction with antithrombin III, which results in 
inactivation of thrombin and other coagulation factors (Lindahl et al. 1979, Thunberg et al. 1982). A 
specific carbohydrate sequence (pentasaccharide) of the heparin molecule is essential for this, and 
must thus be preserved through the stent coating process. First tested as a coating in 
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cardiopulmonary circuits with favourable results, Duraflo II® coating applies ionic bonding, in 
which heparin is releasable from the surface to some extent (De Scheerder et al. 1997, Matsumoto 
et al. 2002). Matsumoto et al. used releasable heparin, and found that the antithrombin activity of 
heparin was dose-dependent. Gao et al. (1996) applied copolymeric PCL/PLA stents impregnated 
with heparin in an experimental model with encouraging results. However, a problem with these 
first two heparin-bonding methods may be the uneven or unpredictable content and activity of 
bound heparin. 
 
 
TABLE 1. PRINCIPLES OF HEPARIN BONDING 
  
         
 
        
 
 
MECHANISM 
  
USE 
  
  
       
IONIC 
 Heparin activity is retained on the Extracorporeal circuits 
BONDING surface. Heparin release occurs  Stent coatings  
  to some extent.      
         
         
POLYMER Heparin is released according to  Experimental stent  
MIXTURE 
 (co)polymeric degradation.  coatings   
         
         
COVALENT  The anticoagulative activity of  Stent coatings  
BONDING heparin depends on preservation  Coatings in bypass  
  of free antithrombin binding sites  grafts   
  of the molecule. Heparin in not      
  released from the surface.     
 
 
Classic covalent bonding of heparin is applied in Carmeda® coatings (Larm et al. 1983, 
Hårdhammar et al.1996, Serruys et al. 1996). With this kind of coating, approximately 15% of the 
end-point-attached heparin molecules preserve the high affinity to bind antithrombin III, responsible 
for the compound’s anticoagulant activity, which may be significantly reduced by sterilisation but 
not by deployment (Hårdhammar et al. 1996). Corline® coating uses more advanced technology in 
which the surface is built upon a macromolecular conjugate of heparin. It is covalently bonded such 
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that the antithrombin III binding sites are not involved in the covalent bonds but free to interact with 
antithrombin III (Kristensen et al. 2003, Johnell et al. 2002, van der Giessen et al. 1999, Christensen 
et al. 2001). In Hepamed® coating, a covalently-bound heparin represents the fourth layer of all 
covalently bound layers (Vrolix et al. 2000).  
 
Among other antithrombogenic coatings, Seifert et al. (1997) examined properties of surface-
immobilised hirudin on polylactide-polyglycolide polymers in vitro, and found that the blood- 
contacting properties of the polymer were improved. Antithrombotic and antirestenotic 
hirudin/prostacyclin analogue (Iloprost®) coating on metallic stents have also been suggested to 
exhibit excellent blood compatibility in animal experiments (Alt et al. 2000). Hirudin is a potent 
blocker of thrombin, the key molecule in the initiation of platelet aggregation and cross-linkage of 
the fibrin clot. An analog of proctacycline (PGI2), Iloprost®, accounts for part of the 
thromboresistance of the intact endothelium and the vessel wall (Alt and Selinger 1998). Other 
biocompatible stent coatings may be hyaluronic acid, a nonsulfated glycosaminoglycan component 
of the extracellular matrix (Verheye et al. 2000), and certain anti-platelet agents, such as abciximab 
(c7E3-Fab, ReoPro™) (Baron et al. 2002). 
 
Antirestenotic stent coatings 
Numerous attempts to reduce neointimal overgrowth and restenosis have been performed, yet f ew 
have clinical relevance. These coating compounds include steroids (De Scheerder et al. 1996b, 
Lincoff et al. 1997), angiopeptin analogues (de Scheerder et al. 1996a), methotrexate (Cox et al. 
1992), forskolin (Lambert et al. 1994, Dev et al. 1995), tyrosine kinase receptor blockers 
(Yamawaki et al. 1998), fibrin-film coating (McKenna et al. 1998), titanium-nitride-oxide 
(Windecker et al. 2001), and phosphoryl-cholin (Zheng et al. 1999, Galli et al. 2001, Beaudry et al. 
2001, Grenadier et al. 2002 ), just to mention a few. 
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comparing the same design, the tighter the mesh or the more metal per unit area, the larger is the 
neointimal growth (Tominaga et al. 1992). 
 
4.6. Problems with stents 
One possible complication following stenting is acute or subacute thrombotic occlusion (Sheth et al. 
1996b, Gawatz et al. 1997, Orford et al. 2002). In the modern era, however, thrombogenicity of 
intravascular stents is mainly prevented by efficacious medical therapies. In the future, coated stents 
may further diminish the rate of thrombosis, and even reduce the need for systemic medication. The 
treatment of restenosis, related to both progression of the disease and to neointimal proliferation 
leading to in-stent restenosis, has for a long time been an inevitable problem. It may be greatly 
facilitated, or even resolved, by the use of novel antiproliferative stent coatings (Morice et al. 2002, 
Park et al. 2003, Schampaert et al. 2004) and, in the future, by gene therapy (Feldman et al. 2000, 
Lederman et al. 2002). Although the therapeutic effectiveness of irradiation as a preventive therapy 
in restenosis has been demonstrated, its role may be receeding along with the success of other anti-
restenotic therapies (Tierstein and Kuntz 2001). 
 
Infection, perforation, arteriovenous fistula, and foreign body reactions are previously described 
complications of stent implantation (Therasse et al. 1994, Hearn et al. 1997, Doslouglu et al. 2001, 
Yutani et al. 1999, Smith et al. 2001, Korpas et al. 2002). Immunologic reactions are possible but 
not yet identified with stents. It has also been postulated that the corrosion of metals may cause in-
stent restenosis, but its incidence after clinical stenting is unknown (Ryhänen et al.1997, Shih 
2001). One suggestion has been that stents may impair late luminal positive remodelling, and 
therefore, are perhaps not needed beyond six months after implantation (Hoffmann et al. 1996), 
although some clinical data suggest the contrary (Serruys et al. 1998, Kimura et al. 1996). It is, 
however, inevitable that by increasing stent implantation, treating longer lesions, and younger 
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patients, it is possible to create individual inner “full metal jackets”, which may disturb further 
interventions or operations (Colombo and Karvouni 2000). 
 
 4.7. Models in the measurement of PTA and stent-induced vascular response 
Reports of vascular response to PTA and stenting in humans are limited by a lack of tissue 
examination (Farb et al. 2002, Moreno et al. 1996). Animal studies may be used to answer specific 
biological questions that can help understanding of human pathology (Welt and Rogers 2002). In 
addition to various rat models porcine coronary, canine coronary/femoral artery, and rabbit iliac 
artery in vivo models have been applied to examine vascular wall reactions to PTA and stenting 
both in normal and atherosclerotic vessels. Another way of investigating vascular response is via 
periprocedual venous sampling and/or direct arterial blood sampling from the target area 
(Mickelson et al. 1996, Neuman et al. 1996).  
 
4.8. Imaging of luminal dimensions in the stented area 
Clinically, angiography has still been “the golden standard” whenever post-stenting imaging is 
required. Intravascular ultrasound (IVUS) has gradually gained popularity in clinical practice, and 
in experienced hands it has become one of the most reliable methods to visualise luminal and even 
vessel wall pathology, very often giving more information of the target vessels than conventional 
angiography (Oemrawsingh et al. 2003). Visualisation of luminal dimensions in a stented area by 
magnetic resonance angiography (MRA) remains problematic. With current magnetic resonance 
(MR) scanners, metallic stents are usually safe for imaging, but metals may cause a “black hole” 
artifact due to magnetic field distortions, and evaluation of luminal patency can be limited (Hug et 
al. 2000). Therefore, contrast-enhanced computer tomography (CT) can be useful in depicting 
intraluminal signals of SS stents, whereas tantalum stents may be imaged by MRA (Amano et al. 
1999). Artificial narrowing in the nitinol stented area is also possible in contrast-enhanced MRA. 
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Indirect luminal “visualisation” can also be achieved by different types of flow measurements, often 
based on ultrasound imaging. 
 
4.9. Experimental models to test stent thrombogenicity 
There are several possibilities to investigate stent thrombogenicity in vitro. In a steady state model, 
materials are exposed to various blood components, and in this way basic, material-related 
differences can be assessed (Zidar et al. 1993). Blood perfusion can be used to mimic in vivo 
situations (Beythien et al. 1994, Beythien et al. 1999). With these kinds of models, the effect of 
different stent configurations, coatings, and concomitant medication against platelet deposition and 
coagulation activation can easily be tested. Herrmann et al. (1999) used an elegant ex vivo human 
stasis model to compare differently coated stents, and to assess release kinetics of antithrombotic 
agents and their effect on platelet adhesion and plasmatic coagulation. There are examples where 
experimental results have later been confirmed clinically (Hårdhammar et al. 1996, Serruys et al. 
1998), while other data have not been validated by later human studies (Wohrle et al. 2001).  
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5. AIMS OF THE STUDY 
 
The general goal of this study was to evaluate the utility of polylactide (PLA) as a possible stent 
core material with simple stent prototypes. Additionally, thrombogenicity of uncoated and heparin-
coated PLA in comparison with stainless steel was examined.  
 
The specific aims of this study were as follows: 
 
1. to evaluate the rate of biodegradation and long-term tissue responses of poly-L/D-lactide stents 
in normal rabbit aorta (Studies I-II),  
 
2. to investigate whether PLA disturbs MR imaging after implantation or in the early phase of 
biodegradation, and specifically, whether it is possible to measure intraluminal dimensions in 
the stented area by means of Gadolinium-enhanced MR angiography (Study II), 
 
3. to examine whether there are crucial  differences in blood compatibility between biodegradable 
(PLA) and non-biodegradable (stainless steel) stent materials, by challenging the natural 
anticoagulative factors in static conditions in the presence of foreign material, i.e., a stent strut 
(Study III), 
 
4. to evaluate how configuration and coating of PLA stents affect their thrombogenicity under in 
vitro blood flow conditions (Study IV).  
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6.1.3. Periprocedual antithrombotic medication 
As antithrombotic medication, daily oral acetylsalicylic acid 12.5 mg and ticlopidine 250 mg doses 
began one to two weeks before the intervention, and continued during the first month after surgery. 
Subsequently, daily acetylsalicylic acid was administered until the animal was killed. In addition, 
subcutaneous fractionated heparin (enoxaheparin sodium) was administered three days pre- and 
post-operatively. 
 
6.1.4. Stents 
PLA stents 
The PLA 96L/4D stent was designed at the Institute of Biomaterials, Tampere University of 
Technology, Tampere, Finland. A self-reinforced copolymer of L- and D-lactide (L/D ratio 96/4%) 
was processed into a double spiral helical stent (length 10 mm, strut diameter 0.2 mm) by Bionx 
Implants Ltd, Tampere, Finland. The outer diameter of the stent varied from 2.2 to 2.4 mm with an 
initial lumen of 1.8 to 2.0 mm. Stents were sterilised by gamma irradiation, which results in both 
reduced molecular weight and decreased degradation rate of the material. After processing and 
sterilisation, molecular weights of the specimens were 30 372 daltons. Theoretically, the PLA 
96L/4D stent immediately begins to expand at body temperature and reaches its maximal expansion 
of 1.2 fold its original diameter in 24 hours. The final outer diameter was from 2.6 to 2.9 mm.  
 
Tensile strength of the stent strut specimens was tested with a Lloyd LR 30K (Lloyd Instruments, 
Fareham, England) materials-testing machine. In vitro degradation rate of the stent was tested in 
phosphate-buffered saline. The tensile strength of the strut decreased from 400 Mpa to 135 Mpa in 
six weeks. After 12 weeks the strength was 19% of the initial strength. The stent strut did not swell 
during immersion in the buffer solution.  
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6.1.6. Imaging studies 
Angiography  
Patency of the vessel after PLA stent implantation was determined in Study I by a lateral 
intraoperative angiography (contrast media: Omnipaque® 180 mg/ ml, one projection). Before 
termination, an angiography was performed in the same way.  
 
Magnetic resonance imaging  
All rabbits in Study II were scanned with a Siemens Vision 1.5 T MRI Scanner (Siemens, Erlangen, 
Germany) with the aid of a quadrature knee coil. The abdomen was first imaged in the axial and 
coronal directions with a T1-weighted sequence (TR 760, Te 12, slice thickness 3 mm, 160 x 256 
matrix size) to localise the abdominal aorta and the stented area. The infrarenal aorta was then 
imaged with a 24-sec 3 d flash sequence (Slab/Eff. thickness 47/1.8 mm, one acquisition, matrix 
size: 180 x 256), first without a contrast medium and then three times immediately after an 
intravenous dose of 0.3 mmol/kg gadolinium (Dotarem®, Guerbet, Villepinte, France) to achieve 
the best possible contrast media concentration in the infrarenal aorta. Proximal (1 cm below the left 
renal artery), distal (immediately above the bifurcation), and narrowest infrarenal aortic luminal 
diameters were established with the MR scanner by computerised measurements. The longitudinal 
length of the stent artifact was measured in the same manner. 
 
6.1.7. Histologic assessment 
The stented aorta was cut horizontally, and one half of the stented area was fixed with 4% formalin 
solution for histologic examination, the other half sampled for SEM. Specimens of formalin-fixed 
aortas were buffered overnight in 10% phosphate-buffered neutral formalin. The aortas were then 
imbedded in paraffin through a process of graded concentrations of ethanol and xylene, and 
sectioned with a microtome producing 3 µm-thick sections. After rehydration with xylene and 
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graded concentrations of ethanol, the samples were finally stained with hematoxylin and eosin, van 
Gieson, or elastin stainings. 
 
Staining for elastin enables the assessment of elastin fibers in the tunica media, while van Gieson 
staining determines the relative amounts of fibrous and smooth muscle proliferation of the 
neointima. The van Gieson dye reveals smooth muscle proliferation of the neointima by staining 
smooth muscle orange and collagenous fibrous tissue red. 
 
6.1.8. Scanning electron microscopy 
The other half of the stented area of the aorta was fixed in 2.5% buffered glutaraldehyde solution 
for SEM. After fixation, the tissue samples were dehydrated in ethanol and critical-point dried 
(BAL-TEC Ltd., Balzers, Liechtenstein), mounted on aluminium studs, and coated with gold by 
means of a Jeol JFC-1100 sputtering device (Jeol Ltd, Tokyo, Japan). The samples were then 
examined with a Jeol JSEM-820 scanning electron microscope (Jeol Ltd, Tokyo, Japan) at 4-20 kV 
acceleration voltage. 
 
6.1.9. Statistical analysis   
The numerical data are expressed as mean ± SD (Study II). Variations in the measured indices 
between three groups (PLA- or stainless steel-stented animals, and non-stented animals) of the 
various assessment points (proximal, distal, and narrowest aortic dimensions) were analysed by the 
non-parametric Kruskal-Wallis one-way analysis by ranks (StatisticaTM v. 5.5, StatSoft Inc., Tulsa, 
OK, USA). Non-parametric analysis was chosen due to small sample sizes. The rank sums were 
then used for Dunn’s test at a significance level of 5% (Medstat, Astra Group A/S, Copenhagen, 
Denmark). Values of p < 0.05 were considered statistically significant.  
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6.2. In vitro studies 
The goal of the in vitro studies was firstly to challenge the native anticoagulative factors of human 
blood in the presence of a stent strut, with a steady state model under static conditions. 
Unheparinised and heparinised PLA struts were compared with stainless steel (Study III). To assess 
the procoagulant capacity of platelets, a range of platelet numbers with and without plasma was 
provided. In the measurement of coagulation activation, various crucial markers of the coagulation 
cascade were determined: prothrombin fragments 1+2 (F1+2), thrombin-antithrombin compex 
(TAT), fibrinogen, and thrombin time (TT) (Figure 3). Next, a whole blood perfusion model was 
applied to evaluate the effect of stent design and coating on blood compatibility of PLA stent 
prototypes (Study IV). Furthermore, to mimic the pathophysiology of balloon injury by the collagen 
exposure, the stent-containing segment of the perfusion tubing was precoated with type I collagen 
in the last series of these experiments.  
 
6.2.1. Stent materials and stents 
The Institute of Biomaterials, University of Technology, Tampere, Finland produced all 
biodegradable stent struts and stents, and the heparinisation was provided in cooperation with 
Helsinki University of Technology, Helsinki, Finland. The heparinsodium, derived from porcine 
intestinal mucosa, was provided and analysed by the Sigma Corporation (St. Louis, MO, USA). 
Before the experiments, all biodegradable stent struts and stents were sterilised by gamma 
irradiation.  
 
Stent materials  
One cm stent struts of each material were examined. Stent struts of stainless steel were cut from 
commercially available stainless steel coronary stents. The diameter of the wire was 0.1 mm. 
The PLA stent strut was made of a self-reinforced copolymer of L- and D-lactide (L/D ratio 
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Figure 3. Schematic, simplified presentation of platelet response and coagulation activation 
relevant to the present study. The markers measured are in square boxes. The cascade of fibrinolytic 
mechanisms is not shown.  
ATIII = Antithrombin III, F1+2 = Prothrombin fragments 1+2, FXa = factor Xa, FXIII = Factor 
XIII, TAT = Thrombin-antithrombin complex, TT = Thrombin time 
 
 
 
 
96/4%). By a special die-extrusion coating process, at a temperature of 60°C, the melt coating 
material, a heparin-blended (5801 IU/g) copolymer of ε-caprolactone and L-lactide (Hepa 
P(CL95/L-LA5, molecular ratio of ε-caprolactone to L-lactide: 95:5), was extruded directly onto the 
 39
PLA strut to obtain Hepa P(CL95/L-LA5)-PLA stent struts. The diameters of the PLA and Hepa 
P(CL95/L-LA5)-PLA struts were 0.2 mm and 0.3 mm. 
 
Stents  
In Study IV, seven different biodegradable stents of two types of configurations, either self-
expanding (double spiral) or partly self-expanding/partly balloon-expandable (braided), were 
examined. Standard balloon-expandable coronary stents (size 3.0-3.5 mm, length 10 mm, wire 
diameter 0.1 mm, NIRTM, Medinol Ltd, Natick, MA, USA) of stainless steel were used as controls 
for each series of perfusion.  
 
Double spiral PLA stents 
 
A self-reinforced copolymer of L- and D-lactide (L/D ratio 96/4; PLA96L/4D) was processed into a 
self-expanding double spiral helical stent. The maximal outer diameter of the stent before vs. after 
expansion was 2.5 vs. 3.0 mm when uncoated and 3.0 vs. 3.6 mm when coated. The length of each 
stent was 10 mm. 
 
 Braided PLA stents 
  
Self-reinforced PLA 96L/4D stent struts were braided into the form of a partly self-expandable, 
partly balloon-expandable stent consisting of 16 struts. The braids were heat set on metal mandrels 
having a diameter of 3.2 mm and cut to a length of 10 mm. 
 
The spiral PLA stents were heparinised by the die-extrusion coating process, a heparin-blended 
copolymer of ε-caprolactone and L-lactide [Hepa P(CL/L-LA)] serving as coating material. The 
heparin coating of braided PLA stents were performed either by die-extrusion, or by using acetone 
as dissolvent and a copolymer of ε-caprolactone and D,L-lactide [P(CL/D,L-LA)] as coating 
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polymer. The original heparin potency before all processing was 179 ± 4 USP units/mg. The 
coating of stents with P(CL/D,L-LA) was performed in the same manner without heparin. 
 
6.2.2. Assessment of stent-attached heparin 
The amount of heparin leaching from the stent strut and stents was assessed with the Blyscan 
glycosaminoglycan assay® (Biocolor Ltd., Belfast, Northern Ireland). The strut-attached heparin 
was measured before and immediately after the experiment (Study III). Three parallel heparinised 
stent struts were incubated as described in section 6.2.4. for platelet deposition or coagulation 
activation experiments. The heparin content before the incubation was 3.80 ± 0.30 µg/strut (mean 
40.00 µg/cm2). At the end of the platelet deposition assay, it was reduced to 0.15±0.03 µg/ strut 
(mean 1.58 µg/cm2), and after coagulation activation assessment to 0.13 ± 0.05 µg /strut (mean 1.42 
µg/cm2).  
 
Assessed by the same assay (described above), the estimated heparin content per stent was 8.7 µg 
for the spiral coated PLA stents, 6.0 µg and 8.3 µg for the two Hepa P(CL/L-LA)-coated PLA 
stents, and 11.4µg for the braided P(CL/D,L-LA)-heparin-coated PLA stents before perfusion 
(Study IV).  
 
6.2.3. Blood collection and preparation 
The Institutional Review Board of the Wihuri Research Institute approved the study. Blood was 
donated by 40 healthy volunteers who had not taken any medication during the previous 10 days 
and who had been fasting 8 h before sampling. After resting for 15 minutes, the blood samples were 
obtained with a free-flowing technique with the first 3 ml discarded. Samples were collected 
through venipuncture from the antecubital vein via an inserted polytetrafluoroethylene cannula 
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(Viggo®) into polypropylene tubes. Platelet counts and haematocrit were determined with a 
Thrombocounter Coulter T-540. 
 
In Study III, for gel-filtered platelets (GFP), six volumes of free-flowing blood were collected into 
one volume of acidic citrated dextrose, pH 4.5. Nine volumes of blood were collected into one 
volume of either 1) 3.2% sodium citrate for plasma specimens or 2) 30 µmol/l  D-phenylalanyl-L-
prolyl-L-arginine chloromethyl ketone (PPACK) for platelet-rich plasma (PRP) specimens in 
platelet deposition studies, or 3) 0.5 µmol/l or 0.75 µmol/l PPACK for PRP and platelet-poor 
plasma (PPP) for the assessment of coagulation activation. PRP was separated from blood by 
centrifugation (180 x g, 12 min, 22ºC).  PPACK (Calbiochem-Novabiochem Corp, San Diego, CA, 
USA) is a direct thrombin inhibitor without chelation of ionic calcium or magnesium necessary for 
platelet adhesion receptors.  
 
In Study IV, nine volumes of blood were collected into one volume of 30 µmol/l PPACK for 
preparing PRP, which was separated from blood after centrifugation in the same manner as in Study 
III. Platelets in PRP were labelled with 0.45 µl of 5-hydroxy[G-3H]tryptamine creatinine suphate 
/ml PRP (3H-serotonin, 10 nmol/l, Amersham Pharmacia Biotech UK Limited, Buckinghamshire, 
England, UK) by 15 min incubation at 37ºC. Before the perfusion, the labelled PRP and the 
remaining blood cells were recombined and incubated at 22ºC for 30 min as previously described 
(Mustonen and Lassila 1996). CaCl2 was added to the priming solution (phosphate buffered saline, 
PBS) at 0.8 mmol/L and MgCl2 at 0.5 mmol /l. For scanning electronmicroscope examination, all 
the same procedures were performed with the exception of platelet labelling. 
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6.2.4. Platelet deposition analyses (Study III) 
GFP was prepared from PRP after a single washing step in the presence of prostaglandin E1 (25 
ng/ml) and apyrase (1 U/ml) (Sigma), and the platelet suspension was then passed through a 
Sepharose CL-2B column (Pharmacia LKB) and eluted to Hepes buffer without divalent cations. 
Platelets were labelled with 3H-serotonin at a concentration of 10 nmol/l at 37°C for 15 min. The 
labelled platelets were adjusted to 100, 300, or 500 x 106/ml of Hepes buffer, supplemented with 
Ca2+ (2 mmol/l) and Mg2+ (1 mmol/l) just prior to the assay. The stent struts were placed in flat-
bottom multidishes (NUNC) precoated with 2% human serum albumin (HSA) and loaded with 
0.5 ml of the various platelet suspensions. The suspensions were: two densities of GFP, 300 x 
106/ml and 500 x 106/ml, representing normal and supranormal platelet densities; GFP 500 x 106/ml 
diluted 1:1 with 3.2% platelet-poor plasma (PPP); and PRP anticoagulated with PPACK either at 
100 x 106/ml or at 300 x 106 platelets/ml. After a 20 min incubation at 37°C with a slowly rotating 
motion (70 rotations per minute), the struts were removed, washed three times by dipping into PBS, 
and the 3H-serotonin activity of the stent struts measured in a liquid scintillation counter (Rackbeta, 
Wallac, Turku, Finland). The number of platelets deposited on the strut area was calculated from 
the number of platelets added and from their specific activity. Additional samples of GFP-incubated 
struts (at both GFP densities, 300 x 106/ml and 500 x 106/ml) were fixed with 2.5% glutaraldehyde 
solution for SEM.  
 
6.2.5. Coagulation activation (Study III) 
PRP was prepared as described and finally adjusted to a platelet density of 300 x 106/ml. Limited 
anticoagulation was provided by PPACK at two final concentrations: 0.5 µmol/l and 0.75 µmol/l. 
The concentrations of Ca2+ and Mg2+ were physiological. The stent struts were placed in HSA-
coated flat bottom multidishes, and loaded with 1 ml of either of the four different PRP/PPP 
suspensions. As controls, the same measurements were performed for incubated PRPs and PPPs 
 43
without a stent strut. After 20 min incubation (37°C, 70 rotations per minute) the reaction was 
halted by putting the samples on ice. Thrombin time (TT) was measured in the plasma (PRP or 
PPP) in which the stent struts had been incubated with a Coagulometer Amelung KC 1 A (Heinrich 
Amelung GmbH, D-4920 Lemgo 1-Lieme, Germany). Likewise, fibrinogen was assessed by the 
functional method of Clauss, and enzyme-linked immunosorbent assays (ELISAs) were applied to 
determine prothrombin fragments 1+2 (F1+2) and thrombin-antithrombin complex (TAT) (Dade 
Behring, Marburg, Germany). The upper limit for the follow-up of TT values was 300 seconds. 
 
6.2.6. Description of the whole blood perfusion model (Study IV) 
Stents were implanted with appropriately sized balloon catheters into a polyvinylchloride (PVC) 
tube (Ø3.2 mm, Sorin Biomedica, Espoo, Finland), with or without precoating the tube with fibrillar 
type I collagen (Collagen Reagent Horm, Nycomed Pharma GmbH, Unterschleissheim, Germany). 
Each experiment was repeated five times using blood from different individual donors. The order of 
a stent perfused inside each series was randomly chosen. Blood from 25 individual donors was used 
for the following perfusion comparisons, and from four donors for representative SEM: 
 
 Pilot group: 
 A stainless steel stent was compared with a PVC-tube without a stent and with a spiral PLA stent.  
Study groups (I-IV): 
A stainless steel stent was compared with  
 I) a spiral PLA stent and a spiral PLA stent coated with a heparin-blended copolymer of ε-
caprolactone and L-lactide [Hepa P(CL/L-LA)]; (heparin dose: 8.7 µg/stent), 
II) a braided stent with Hepa P(CL/L-LA)-coating (heparin dose: 6.0 µg/stent) and a braided  
 
stent with  Hepa P(CL/L-LA)-coating (heparin dose 8.3 µg/stent), 
 
 44
III) an uncoated braided PLA-stent, a copolymeric ε-caprolactone and D,L-lactide [P(CL/D,L-LA)]-
coated stent, as well as with a P(CL/D,L-LA)-heparin-coated stent (heparin dose:11.4 µg / stent),   
IV) stents with the same design and coating as in III), but the stent-containing segment of the PVC-
tubes was precoated with fibrillar type I collagen before implantation of the stents. 
 
The total length of the closed perfusion tubing was 83 cm. The temperature of the primer, the blood, 
and the stent-containing segment were stabilised in a water bath at 37ºC for 5 min. The perfusion 
was initiated with cation-containing PBS (30 s), and continued with a roller pump at a flow rate of 
30 ml/min for 90 s. To finish the perfusion, PBS-rinsing was repeated (30 s) and the stent-
containing segment of the tube was cut and rinsed with PBS. The deposited platelets with their 3H-
serotonin activity were measured as described in section 6.2.4. Before and after perfusion, plasma 
3H-scintillation (serotonin release), and total blood 3H-scintillation activities were determined as 
described elsewere (Mustonen and Lassila 1996). To assess the extent of coagulation activation, 
prothrombin fragments F1+2 were measured just prior to the perfusion and again after 75 seconds 
of blood perfusion by ELISA, as in section 6.2.5. 
 
6.2.7. Scanning electron microscopy (SEM) 
The morphology of the adhering platelets on the different stent struts and stents were investigated 
qualitatively by SEM. In Study III, after incubation with GFP at a platelet density of either 300 x 
106/ml or 500 x 106/ml, the stent struts of the different materials were rinsed with PBS. After 
fixation with buffered glutaraldehyde solution (2.5%), the struts were dehydrated in ethanol and 
critical-point dried (BAL-TEC Ltd, Baltzers, Liechtenstein), mounted on aluminum studs, and 
coated with gold. To qualitatively investigate the morphology of adhering platelets on the different 
stents in Study IV, the perfused stents were washed as described above with PBS and fixed with 
buffered glutaraldehyde solution for 90 min and then immediately with 1% osmiumtetroxide for 60 
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min. Thereafter, the stents were dehydrated in ethanol and critical-point dried, mounted on 
aluminum studs, and coated with platinum. Scanning electron microscopic analyses were performed 
with a Jeol JSEM-820 Scanning Electron Microscope (Jeol Ltd., Tokyo, Japan; in Study III) and a 
Zeiss Digital Scanning Microscope 962 (Oberkochen, Germany; in Study IV).  
 
6.2.8. Statistical analyses 
All numerical data are expressed as mean + SD The variation in the measured indexes between the 
different stents struts and stents were analysed by non-parametric analysis (Kruskal-Wallis one-way 
analysis), and the Dunn’s test, as in the animal studies (described in section 6.1.9). 

 47
9-12 months after the implantation (n = 11) hydrolysation of the stent was histologically evident, 
with no signs of fragmentation. A mild foreign body reaction with scarce giant cells and some 
macrophages was evident in 4/11 sampled aortas, but one aorta had a persistent inflammatory 
reaction with lymphocytes, macrophages, and very few giant cells. Some calcium deposits were 
detectable in the fibrotic tissue, and some vessels were evident both in the neointima and the 
muscular layers. In one aorta, the area of calcium deposits resembled the chondroid metaplasia, 
previously found in another aorta sampled at three months after implantation. 
 
Degradation of the stent had proceeded with some cells visible inside the material from 20 to 22 
months after implantation (n = 2). Endothelium was intact, and fibrosis resembled that as at one 
year with haemosiderin-containing macrophages and calcium accumulation in the neointima. Sparse 
areas of fibrosis  showed smooth muscle cell proliferation. From two years after implantation (n = 
3), the material appeared largely hydrolysed and was no longer detectable under polarising light, as 
at earlier time points. Fibrotic proliferation was less active than earlier, and no signs of 
inflammation were evident. Mild smooth muscle cell proliferation was detected in the fibrous 
tissue. Some areas of the muscular layer were thinned resulting in good luminal preservation. 
Calcifications and haemosiderin accumulations were evident as at previous assessment points.  
 
Scanning electron microscopic assessment 
Similar to the histologic findings, endothelium appeared to cover the stented area by one month 
after implantation, which was also true at later time points. The stent seemed to be well-fitted  
subendothelially, with the lumen retaining its patency. 
 
7.2. Assessment of luminal diameters after PLA-stenting by MRA 
Stainless steel caused a signal loss in the stented area, as expected, making evaluation of luminal 
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diameters impossible. In contrast, PLA stents caused no magnetic field distortion, allowing 
detection of luminal patency in all 12 animals. In the follow-up group of PLA-stented rabbits, 5/6 
survived through to the end of the 12 month follow-up. PLA-stenting allowed assessment of 
luminal dimensions at various time points up to one year. The exact location of the PLA stents, in 
regard to renal and iliac arteries, could only be established at necropsy. The proximal dimensions (1 
cm below the left renal artery) of the control and those groups studied immediately post-operatively 
did not differ, while the distal dimensions (at aortoiliac bifurcation) were narrower in both groups 
implanted with a stent. This difference was significant only between non-operated controls and 
those implanted with a PLA stent (p < 0.01). The narrowest region of the aorta was generally in the 
stented area, and probably at the line of suturing. No significant differences in aortic measurements 
emerged during the follow-up period, with a non-significant tendency for normalisation of the 
narrowest diameter towards the end of the study. 
 
7.3. Material-related haemocompatibility of PLA 
In Study III, a steady state model was used to assess possible material-related rheological 
differences between stainless steel, uncoated PLA, and heparin-coated PLA. In general, in 
comparison with stainless steel, both uncoated PLA and heparin-coated PLA stent struts appeared to 
possess favourable blood compatibility. 
 
Platelet deposition on stent materials in different platelet suspensions 
The stainless steel strut accumulated significantly more platelets than did the PLA strut, with a 
physiological platelet count of 300 x 106/ml (p < 0.05). Although a range of platelet numbers, with 
and without plasma, were provided to assess the preocoagulant capacity of platelets, the numbers of 
adhering platelets on SS, PLA, and hepa-P(CL95/L-LA5)-PLA stent struts did not differ 
statistically. 
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At representative SEM assessment, platelets appeared mostly to be uniformly spread or deposited in 
small aggregates with detectable pseudopodia. On the surface of stainless steel stent struts, platelets 
often presented full spreading and likely activation (“fried-egg” appearance), in contrast to platelets 
on PLA surfaces, which only changed shape. Although platelets on heparin-coated PLA appeared to 
show the least extent of pseudopodia formation in general, in occasional samples more platelets 
were visible on these stent struts than on either SS or PLA. 
 
Coagulation activation in PRP/PPP on stent materials 
 
In no assessment did fibrinogen content in plasma incubated with or without a stent strut differ. Due 
to limited anticoagulation with the low concentration of PPACK, thrombin -antithrombin complex 
(TAT) revealed varying levels of coagulation activation, with control values (i.e. values for 
incubation suspensions without a stent strut) similar to PLA. In the assessments in which platelets 
were in contact with stainless steel, TAT values tended to be higher. However, none of these 
differences were statistically significant. Similarly, with prothrombin fragments 1+2 (F1+2), a 
tendency for the highest values to occur with stainless steel and the lowest with Hepa P(CL95/L-
LA5)-PLA was observed in all assessments. This difference was significant only at a low 
concentration of PPACK in PRP, under the conditions prone to generate the most thrombin. Control 
values most closely resembled PLA in their generation of F 1+2.  
 
Under all conditions, thrombin time (TT) was significantly prolonged by the hepa-P(CL95/L-LA5)-
PLA in comparison with TT for stainless steel. The difference in TT between the PLA and Hepa 
P(CL95/L-LA5)-PLA reached statistical significance in the presence of platelets employed in PRP 
at 0.5 µmol/l PPACK, or in PPP at 0.75 µmol/l PPACK.  
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collagen platelet-associated local fibrin accumulation was detected on all stent materials. Heparin-
coating appeared to diminish this fibrin deposition.  
 
Morphologic findings in SEM 
In accordance with the quantitative data, more platelets deposited on biodegradable stents than on 
stainless steel stents in general (Figure 4). As indicated by reduced pseudobody formation and 
platelet spreading, there appeared to be less platelet activation on braided PCL-PLA-heparin-coated 
PLA stents than on uncoated braided PLA stents. In occasional samples the metallic surface showed 
more ballooning membranes than did any other stent. Platelet aggregates of varying size were 
detectable on all stent surfaces, with barely enmeshed fibrin. As in the quantitative analysis, the 
number of platelets deposited in the presence of collagen was clearly higher than in its absence.  
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Figure 4. Representative SEM after whole blood perfusion.  The stent-containing segment of the 
perfusion tube was precoated with fibrillar type I collagen. Platelet deposition presented on A) 
uncoated braided PLA stent, B) polycaprolactone-D,L-lactide coated PLA stent, C) 
polycaprolactone-D,L-lactide-heparin coated PLA stent, and D) stainless steel stent. Magnification 
1000x. Bar in D= 20µm. 
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8. DISCUSSION 
 
8.1. Materials and methods 
In order to assess long-term vascular response after stenting, an adult rabbit model was chosen, 
because the animal studies were planned to last at least two years, and therefore a porcine model 
would have been more difficult to manage. A miniswine model would have been an alternative. As 
the aim was to assess the effect of intravascular biodegradation of the material on vascular wall, 
normal rather than atherosoclerotic vessels were examined. With the lack of a percutaneous 
deployment system for the double spiral stent, the PLA stents were implanted through a surgical 
retroperitoneal approach, thus the vascular trauma induced differed from PTA injury. However, the 
stents were implanted proximal to arteriotomy, into an area of non-denuded endothelium.  
 
The possible effect of early biodegradation of PLA stents on magnetic resonance imaging was 
assessed in Study II. Non-operated animals and stainless steel (SS) stented animals were compared 
with PLA-stented rabbits. Other types of stents (e.g. tantalum or nitinol) could also have been 
chosen, as the artifact size may have been smaller than with SS stents. In addition, all animals could 
have been imaged prior to operation to obtain individual reference measurements. Such a protocol 
was not employed, as the aim of the study was to examine the effect of biodegradation, not surgery, 
on MR imaging. Furthermore, another reason was to limit the number of experiments per test 
animal. For the same reason, conventional follow-up angiographies were not used for comparison 
with MRA. In urologic applications, barium sulphate has been used to mark the PLA stent edges, 
but as this agent is not suitable for vascular application and no other marking systems were 
available for PLA stents, aortic measurements were performed by assessing proximal (1 cm below 
the left renal artery), distal (at aortoiliac bifurcation), and narrowest luminal diameters at the stented 
area. 
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(Schwartz et al. 1992), and intimal thickening can be avoided by preservation of endothelium 
(Fishman et al. 1975, Clowes et al. 1983, Stemerman et al. 1977).When PTA and/or, experimental 
endothelial denudation, are used, metallic stents may induce severe chronic inflammation (De 
Scheerder et al. 1997, Barth et al. 1996), and granulomatous or significant foreign body reaction 
(Farb et al. 1999, Kornowski et al. 1999). In the current rabbit aorta model, tissue reactions were 
assessed in 26 animals, with 15/26 rabbits followed up for at least 12 months. All but one remained 
patent through the long-term follow-up, and in two aortas there was a chondroid metaplasia in the 
vessel wall; in one of these cases causing mild luminal reduction at three months after implantation. 
The same kind of rare condition has previously been described in humans related to long-term 
venous catheterisation (Dvorak et al. 1999). Only a mild inflammatory reaction was present in all 
aortas sampled up to six months. From that point, inflammatory reaction declined with proceeding 
biodegradation and neointimal formation, but one aorta presented a persistent inflammatory reaction 
at one year after stent implantation. All other (16) aortas sampled after the onset of biodegradation 
(≥ 9 months) presented mild or no signs of inflammatory reaction in the vessel wall with advancing 
stent disintegration. 
 
Poly-L-lactide (PLLA) has been well tolerated in a dog femoral artery model, and a mild tissue 
reaction similar to that in the current series has been described (Zidar 1994). Instead, polyglycolic 
acid (PGA) stents, which degrade much faster (in 6 weeks), evoke strong vessel wall reaction with 
possible serious complications, and therefore pure PGA stents do not appear recommendable for 
vascular applications as stent core material (Susawa et al. 1993). As it has earlier been pointed out, 
increasing degradation time may positively correlate with tissue compatibility, presumably because 
gradual, slow degradation reduces both the immune and the inflammatory responses. Similarly, 
stents coated with higher molecular weight PLLA were associated with less severe vascular 
response and acute and chronic inflammation than stents coated with lower molecular weight PLLA 
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in a porcine model (Lincoff et al. 1997). The present investigation suggests that poly-L/D-lactide 
stents with a final molecular weight (after sterilisation) over 30 000 Da are quite well tolerated in 
rabbit arteries. However, whether this holds true in human vascular tissue awaits further research. In 
the future, tailoring stent manufacture, affecting degradation time by searching for new processing 
and sterilisation methods, and producing copolymeric core materials may help in minimising the 
vascular wall reactions due to biodegradation (Blindt et al. 1999).  
 
Nowadays, it is well accepted that the development of restenosis greatly depends on the result of 
complex interactions with activated platelets, injured endothelial cells, leukocytes, inflammatory 
chemokines and cytokines, and endothelial growth factors, with inflammation playing a pivotal role 
linking early vascular injury to neointimal hyperplasia and late lumen loss (Weyrith et al. 2002, 
Sousa et al. 2002, Welt and Rogers 2002). After coronary stent placement in humans, neutrophils 
are found surrounding the struts in the early phase, but also macrophages and lymphocytes are 
detectable. After the first month, neutrophils are absent but chronic inflammatory cells 
(macrophages and lymphocytes) are present, even at six months after the procedure (Farb et al. 
1999). Furthermore, the severity of inflammation is associated with the underlying arterial wall 
morphological status: stent struts penetrating necrotic lipid-rich plaques, or related with damaged 
media cause more severe inflammatory response than struts in contact with fibrous plaques. The 
long-term (≥ 9 months after stent implantation) postmortem data has demonstrated that disruption 
of the arterial media and lipid core penetrating stent struts correlates with chronic inflammation, and 
finally with greater neointimal growth (Farb et al. 2002). Interestingly, peristrut neoangiogenesis, 
first described in humans in the same report, appeared to be strongly associated with inflammation, 
but not with neointimal thickness. The authors suggested, on the basis of former studies (Wysocki 
et al. 1998, Hausner et al. 1999, Gill et al. 2001, Couper et al. 1997, Brasen et al. 2001), that 
neovascularisation may have been stimulated by vascular endothelial growth factor (VEGF) 
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released by inflammatory cells, and the presence of neovessels could offer a potential target for 
antirestenotic therapies. In Studies I and II, scarce vessels in the neointima as a sign of 
neovascularisation were detectable in samples from six months after stent implantation, but they did 
not seem to be particularly associated with inflammation. As normal, non-atherosclerotic aortas 
were examined after implantation of a slightly self-expandable stent in an area of intact 
endothelium, no further conclusions can be drawn from the current results.  
 
8.3. Magnetic resonance imaging after PLA stenting 
Contrast enhanced magnetic resonance angiography has become a highly accurate method of 
diagnosing vascular abnormalities of the thoracoabdominal and peripheral vessels (Joarder and 
Gedroyc 2001). Its use in the assessment of supra-aortic and coronary artery lesions is on the 
increase (Loewe et al. 2004, Maintz et al. 2004). Due to magnetic field distortions, stents cause 
considerable artifact and therefore evaluation of luminal patency often remains limited in the 
stented area (Amano et al. 1999, Hug et al. 2000, Lenhart et al. 2000). One assumption in the 
beginning of the current study was that the implanted PLA stents would be detectable by high field 
(1.5 T) MR scanners, as are orthopaedic PLA screws with a molecular weight of 50 000 Da  
(Lohman et al. 1999). Although this was not true for PLA stents, evaluation of luminal diameters 
throughout the study, up to the early phase of biodegration, was clearly possible. Furthermore, the 
measurements in the PLA-stented follow-up group appeared to be reproducible: no differences in 
aortic dimensions emerged during 12 months’ follow-up, although there was a non-significant 
tendency towards luminal normalisation in the narrowest area with advancing stent hydrolysation.  
The pixel size of the scanner was the most accurate available for the study. In small calibre-vessels, 
a change of one pixel tends to correspond to a 20-25% change in luminal dimensions and therefore, 
the differences in the aortic diameters between the groups may be less significant. 
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8.4. Haemocompatibility 
Signs of blood compatibilty of PLA and stainless steel were assessed by two in vitro models with 
human blood, a steady state model (Study III) and a whole blood perfusion model (Study IV). In all 
studies, strut thickness of PLA stents represented the diameters of the intravascular stent prototypes 
designed for experimental application. When compared with control metallic wires (strut diameter 
0.1 mm), PLA struts were two to three times thicker (strut diameter 0.2-0.3 mm). Even so, the data 
from the platelet deposition study showed that at physiological platelet densities, more platelets 
adhered to stainless steel than to PLA stent struts/strut area. In addition, as evidenced by platelet 
appearance in representative SEM, platelets on PLA struts showed less activation than on stainless 
steel struts. Furthermore, heparin coating appeared to strengthen this effect of minimal platelet 
activation in SEM, but quantitively the number of deposited platelets on heparin-coated stent struts 
was not diminished. In accordance with this result, Beythien et al. (1999) have shown that heparin 
coating may not diminish the detectable platelet activation, but it can delay the time until stent 
thrombosis.  
 
In the assessment of coagulation activation, fibrinogen levels of all materials remained similar to 
control values (i.e. values for incubation suspensions without a stent strut), as a sign of minimal 
coagulation activity. In addition, the values of prothrombin fragments F1+2 for PLA resembled 
those of control values, which tended to be higher for SS struts, but this difference was not 
significant. The thrombin-time values were significantly prolonged in all assesments for heparin-
coated PLA in comparison with stainless steel, which illustrates that the anticoagulant activity of 
heparin was preserved after the coating process, also under the most thrombogenic conditions (i.e. 
in the presence of platelets). Both thrombin-antithrombin complex and F1+2 values appeared to be 
lower for heparin-coated PLA than for SS/PLA surfaces. The difference was statistically significant 
only for F1+2 at 0.5 µmol/l PPACK/PRP, indicating that in the presence of platelets under limited 
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directed towards this purpose, and experimentally the blood compatibility of both SS and polymeric 
surfaces appears to be improved (Hårdhammar et al. 1996, Seifert et al. 1995, Alt et al. 2000, 
Herrmann et al. 1999). Although experimental studies have suggested that controlling the formation 
of mural thrombi may reduce neointimal overgrowth or restenosis (Matsumoto et al. 2002, 
Unterberg et al. 1995, Tsuchikane et al. 1999), clinical data have not yet confirmed these findings 
(Wohrle et al. 2001, the ERASER investigators 1999).  
 
Instead of ionic or covalent bonding of heparin on stents (Table 1), polymer-blended heparin 
leaching from a stent surface was applied in Studies III and IV. Locally delivered heparin may 
diminish platelet deposition (Kauhanen et al. 2000, Olsson et al. 2002, Azrin et al. 1994), and in 
particular, large heparin proteoglycans are highly effective in controlling thrombus growth. To 
reduce platelet deposition on stent surfaces, Matsumoto et al. (2002) used releasable multilayer-
heparin with a dosage/stent approximately four to eight times greater than in Study IV. They found 
platelet deposition to be diminished, and the effect depended significantly on the heparin dose. The 
earlier, somewhat disappointing clinical results with ionically or covalently immobilised heparin 
may partly result from the dual role of immobilised heparin – it may act in initiating the intrinsic 
pathway of coagulation, despite the antithrombin enhancing activity (Blezer et al. 1998). Moreover, 
binding competition of antithrombin III with other heparin-binding proteins may diminish the 
anticoagulant activity of surface-immobilised heparin in plasma, and plasma proteins adsorbing to 
heparinised surfaces may also inhibit heparin activity (Van Delden 1996). In accordance with 
earlier data, a recent study demonstrated how blood compatibility can be improved by gradually 
increasing the concentration of covalently immobilised heparin on a biomaterial surface (Andersson 
et al. 2003). 
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8.5. Stent configuration and coating 
Stent design affects both platelet activation and neointimal proliferation (Gurbel et al. 2002, 
Kastrati et al. 2000b, Rogers and Edelman 1995). Thrombotic occlusion of either polymer-covered 
or polymeric stents has also been reported in experimental models (Zidar et al. 1994, Lincoff et al. 
1997, van der Giessen et al. 1996, Susawa et al. 1993). Flexible stents appear to induce less 
neointimal thickness than rigid stents (Fontaine et al. 1994), and decreased hoop strength may 
accelerate neointimal overgrowth (Barth et al. 1996). The current in vitro perfusion study indicates 
that both stent configuration and coating affect platelet attachment also on biodegradable PLA 
stents. There are a few essential differences in material characteristics between metallic and 
polymeric stents, however, which markedly influence fabrication properties (Blindt et al. 1999). 
Dilation of polymeric stents can not be as easily achieved by forming the material at body 
temperature as metallic stents, because of their plastic forming properties. After withdrawal of the 
dilating instrument during metallic stenting, the gained deformation remains. Instead, a polymeric 
stent of a related design will tend to spring back into the original position or even crack and loose 
its mechanical properties. The polymeric helical design allows the reduction of the stent diameter 
by twisting the spiral, and that is why it has been considered one of the most promising 
configurations for polymeric tubular duct devices (Blindt et al. 1999). In the current investigation, 
the double helical spiral configuration was applied for the animal experiments. Additionally braided 
designs, partly self-expandable, partly balloon expandable, were produced for the 
haemocompatibility studies.  
 
There were fewer deposited platelets on stainless steel stents than on PLA stents under all study 
conditions (p < 0.03). PCL-PLA-heparin-coating reduced platelet deposition on both spiral and 
braided PLA stents, and among all biodegradable stents the braided PLA stent coated with 
P(CL/D,L-LA)-heparin accumulated the fewest platelets (p < 0.02). Coagulation activation in 
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circulating blood remained unaltered. In representative SEM, signs of platelet activation on braided 
heparin-coated PLA stents appeared modest when compared with uncoated braided PLA/SS stents. 
Interestingly, in the absence of collagen precoating, the plain P(CL/D,L-LA) coating of PLA stents 
seemed to reduce platelet attachment, but this distinction was lost in the presence of collagen. The 
heparin-coating on braided stents tended to reduce platelet deposition also after collagen exposure. 
The heparin-coating applied in the current investigation was not sufficient to augment blood 
compatibility. It is likely that haemocompatibility of PLA stents will increase when previous 
findings (Matsumoto et al. 2002, Andersson et al. 2003) are taken into account in future stent 
designs and coatings.  
 
8.6. Clinical significance  
The data gained by the current experiments will be helpful in the future in providing tools to 
explore the biocompatibility of new polymeric materials, but the applied bioabsorbable stent models 
are still too far from ideal intravascular stents to be suitable for clinical practice. A delightful result  
was that PLA was at least as haemocompatible as stainless steel as a stent material, but this 
equivalence was lost in the perfusion experiments with the applied stent models, presumably due to 
the technical superiority of stainless steel stents. PLA stent designs were still prototypes, and many 
improvements, including a delicate percutaneous deployment system and an antithrombogenic/ 
antirestenotic stent coating, should be developed before human trials can begin. As a result, a 
copolymeric polyester stent could be created, carrying favourable bioactive substances for 
intravascular therapy, with a strut area less than in the current series, with excellent tissue and blood 
compatibility, strength, elasticity, and appropriate disintegration time. Radiolucency of these 
devices will facilitate the follow-up of target areas by less invasive imaging techniques (MRA, CT), 
and possible long-term complications of permanent non-resorbable devices could be avoided 
(Colombo and Karvouni 2000). Consequently, applications of stents may extend further. 
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Combining all biomedical and technological expertise required, in addition to appropriate financial 
resources, remains a key issue in this effort of creating the ideal vascular stent.  
  
8.7. Future research 
The next goals would be to systematically establish the most suitable biodegradation time of 
selected stent polymers/copolymers for intravascular use, using a miniswine model, as the tissue 
response may greatly depend on the speed of disintegration. Secondly, stent designs should be 
developed further, due to the fact that PLA is not inferior to stainless steel as regards material 
thrombogenicity. However, the real value of adhering platelets in the post-stenting period is 
unknown. In other words, it still remains to be established the relevance of the current in vitro 
findings by other models before we can be certain if the number of platelets, or signs of their 
activation, truly represents blood compatibility in vivo. Thirdly, any material exposed 
intravascularly would be thrombogenic and in the long run, potentially restenotic. Therefore, we 
have to continue to search for intravascular therapies, which in combination with PTA/stenting, 
would support the healing process towards reendothelialisation and positive remodelling (Welt and 
Rogers 2002). Whether this could be achieved by endothelial cell implantation, gene therapy, 
radiation, or drug delivery still remains to be established.  
 
Finally, bioabsorbable materials have been extensively explored for tissue engineering purposes 
during the past decades. Furthermore, computerised technology is gradually revolutionising clinical 
decision making and everyday patient care. With advanced computerised models, it is already 
possible to mimic human pathological conditions. In the future, it may be possible to plan 
individual therapy for vascular abnormalities, in which not only lesion morphology but also 
individual parameters, such as comorbidities, physical condition, vascular resistance, coagulative 
status etc. can be taken into account. At that point, we could end up in a situation where for a 
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certain symptomatic morphological finding a selection of therapeutic options would be available, 
but the choice will be the best for the individual patient. At that time, (permanent) stents may even 
be a legend from history. 
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9. CONCLUSIONS 
 
On the basis of Studies I-IV the following conclusions can be drawn: 
 
1. Biodegradation of poly-L/D-lactide stents in normal rabbit aortas is quite well tolerated. Tissue 
reactions decline following an initial mild inflammatory phase after six months, and neointimal 
proliferation is moderate with preservation of luminal patency. The material is totally replaced by 
fibrosis by two years after implantation. As tissue reactions evoked by a bioabsorbable material 
remain a target-spesific issue, this must be taken into account before human experiments are 
planned. 
 
2. In contrast to stainless steel stents, PLA stents allow measurements of luminal patency by 
magnetic resonance imaging, both immediately after stenting and during the early phase (up to one 
year) of biodegradation. The PLA stent itself is translucent in conventional 1.5 T MRI. 
 
3. PLA appears to be at least as haemocompatible as stainless steel  as a stent material, but this  
equivalence may be lost under flowing conditions whenever stent design and configuration remains 
inferior to stainless steel stents, either due to strut thickness and/or area, or mechanical properties.  
 
4. Releasable heparin-coating seems to reduce platelet adherence to PLA stent surfaces, and this 
effect may be dependent on heparin-dosage.  
 
5. In in vitro human blood perfusion models, coating of the perfusion tubing with type I collagen 
augments the reactivity of platelets in general and may also affect the ability of the coating to act as 
a thromboresistant surface. This must therefore be taken into account when interpreting data from 
previous in vitro studies and in planning future experiments. 
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